- Report
- September 2024
- 150 Pages
Global
From €4414EUR$4,850USD£3,784GBP
- Report
- March 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,784GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Clinical Trials
- August 2024
- 180 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Drug Pipelines
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Drug Pipelines
- July 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Clinical Trials
- June 2024
- 180 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- August 2024
- 200 Pages
Global
From €3521EUR$3,869USD£3,019GBP
- Report
- August 2024
- 150 Pages
Global
From €2538EUR$2,789USD£2,176GBP
- Report
- August 2024
- 200 Pages
Global
From €3521EUR$3,869USD£3,019GBP
- Report
- August 2024
- 150 Pages
Global
From €2538EUR$2,789USD£2,176GBP
- Report
- July 2024
- 110 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- March 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,784GBP
- Report
- July 2024
- 185 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- May 2024
- 184 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- March 2025
- 185 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- March 2025
- 182 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2025
- 180 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2025
- 180 Pages
Global
From €4095EUR$4,500USD£3,511GBP

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer.
Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer.
Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more